PKTX (ProtoKinetix) Change In Working Capital : $0.09 Mil (TTM As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is ProtoKinetix Change In Working Capital?

ProtoKinetix's change in working capital for the quarter that ended in Mar. 2025 was $0.03 Mil.

ProtoKinetix's change in working capital for the fiscal year that ended in Dec. 2024 was $0.08 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

ProtoKinetix Change In Working Capital Historical Data

The historical data trend for ProtoKinetix's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProtoKinetix Change In Working Capital Chart

ProtoKinetix Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Working Capital

Get a 7-Day Free Trial

0.02

-0.03

-0.01

0.08

ProtoKinetix Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Working Capital	Get a 7-Day Free Trial															0.02	-0.01	0.03	0.04	0.03

ProtoKinetix Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

ProtoKinetix Change In Working Capital Related Terms

Thank you for viewing the detailed overview of ProtoKinetix's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

ProtoKinetix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProtoKinetix Inc (OTCPK:PKTX) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

109 W Main Street, Dalton, OH, USA, 44618

Website

https://www.protokinetix.com

ProtoKinetix Inc is a research and development stage biotechnology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins). The AFGP is a compound produced by fish, insects, reptiles, bacteria, and plants that enable survival in freezing temperatures. The company also develops AFGP applications which include regenerative medicine issues including harvesting, processing, storage, and transplanting cells, tissues, and organs and treatments for chronic inflammatory conditions and diseases caused by stress factors, including UV radiation, oxidation, and cryopreservation and hydrogen peroxide.

Executives

Clarence Edward Smith	director, 10 percent owner, officer: President & CEO	1845 COUNTY ROAD #214, ST. AUGUSTINE FL 32084
Michael Richard Guzzetta	officer: CFO	412 MULBERRY STREET, MARIETTA OH 45750
Lachlan Grant Young	10 percent owner	6438 ROSEBERY AVE., WEST VANCOUVER A1 V7W2C6
Edward P. Mcdonough	director	1226 WASHINGTON AVENUE, PARKERSBURG WV 26101
Susan Marie Woodward	officer: CFO	705 DUGAN ROAD, BELPRE OH 45714
Peter Krogh Jensen	director	4656 HOSKINS ROAD, NORTH VANCOUVER A1 V7K 2R1
Ian Thomas Gregory	director	2225 FOLKESTONE WAY, WEST VANCOUVER A1 V7S 2Y6
Ross Laurence Senior	director, officer: CEO	PH-3, 5688 DALHOUISE ROAD, VANCOUVER A1 V6T 1W4
Mark L Baum	director, officer: President	C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

ProtoKinetix Headlines

From GuruFocus

Insider Buying: ProtoKinetix Inc CEO and 10% Owner Clarence Smith Acquires 3,750,000 Shares

By GuruFocus Research • 05-26-2023

Insider Buying: ProtoKinetix Inc CEO and 10% Owner Clarence Smith Acquires 3,750,000 Shares

By GuruFocus Research GuruFocus Editor • 05-25-2023